Abstract 2791: Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastatic prostate cancer
Daemen, Anneleen, Yuen, Natalie, Pankov, Aleksandr, Ariazi, Eric A., Katewa, Subhash D., Duong, Frank L., Wang, Amber, Barkund, Shravani, Kaushik, Shelly, Sun, Jessica D., Friedman, Lori S., Junttila, Melissa R.
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article